Nafamostat Mesilate Injections 100 mg

General information on Japanese Nafamostat Mesylate Injections 100 mg for clotting prevention   

Package details: 10 vials

Manufacturer: Nichi-iko Pharmaceutical Co., Ltd, Japan

Active ingredient: nafamostat mesilate (chemical formula C19H17N5O2)

Medical effect: nafamostat mesilate injections are effective for the following purposes:

1. treatment of the disseminated intravascular coagulation (DIC),
2. preventing clotting of perfusing blood in extracorporeal blood circuit during hemodialysis,
3. preventing the proteolysis of fibrinogen into fibrin,
4. preventing of leaking blood vessels of dengue haemorrhagic fever.

Contraindications and precautions: do not use for pregnant or breastfeeding women. If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Japanese Nafamostat Mesilate Injections 100 mg for clotting prevention      

For patients with disseminated intravascular coagulation (DIC): inject by continuous intravenous infusion for 24 hours.

For patients with need of prevention of perfusing blood coagulation in extracorporeal blood circuit: rinse and fill the inside of blood circuit before the start of extracorporeal circulation. After start of extracorporeal circulation, continuously inject through an anticoagulant injection line.

In any case, the duration of treatment is prescribed by the consulting doctor.

How effective are Japanese Nafamostat Mesilate Injections 100 mg for clotting prevention?

Nafamostat mesilate is a fast-acting proteolytic inhibitor of serine protease. It works as an anti-coagulant and is used in hemodialysis. Nafamostat mesilate also improves dysfunction of organs and treats bleeding caused by blood clotting tendency in the vessels.

Who should use Nafamostat Mesilate Injections 100 mg from Japan?

Nafamostat mesilate injections are widely used in Japan for ultra-short anticoagulation. That’s particularly important in the treatment of DIC and prevention of clotting during hemodialysis. Nearly all Japanese medical institutions use nafamostat mesylate and typically, in a lower concentration that Western doctors (T. Sadahiro, H. Yuzawa et al. Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study. In: Recent Advances in Dialysis Therapy in Japan. 2018, vol 196, pp 209-214). But in any case, the duration of the treatment and the appropriate concentration should be discussed with the consulting doctor.